Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV: A Randomized Controlled Trial.
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The high prevalence of prediabetes in HIV patients is also an outpost event for the further
development of diabetes and cardiovascular events, as well as for the prolonged survival of
HIV patients with metabolic problems and their complications. Based on the well-established
experience in the field of traditional diabetes with prediabetes, the combination of SGLT2
inhibitors can target the pathophysiological mechanisms of HIV-induced metabolic disorders,
and the results of a small pilot study of one of the representative drugs, cabergoline, in
HIV-combined diabetic patients suggest its efficacy and safety in the treatment of
HIV-combined diabetic patients. Combined with the advantages of the concentrated disease
resources of HIV patients in the investigator's unit, this study is intended to use a
single-center randomized controlled clinical trial design, giving the experimental group drug
combined with lifestyle intervention and the control group lifestyle combined with placebo
intervention, to verify whether the combination of cabergoline and lifestyle intervention can
safely and significantly change the clinical outcome of glucose metabolism, as well as the
effect on body weight and pancreatic islet function of patients The study provides top
clinical evidence for the treatment of these patients and suggests a new set of interventions
for patients with HIV combined with prediabetes. No similar studies have been found to be
innovative in the literature search, and the implementation of this study will be of great
clinical value.